Tempus Announces Eight Abstracts Accepted for Presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium

Core Insights - Tempus AI, Inc. is advancing the adoption of AI in precision medicine, particularly in gastrointestinal cancers [1] Group 1: Company Developments - Eight abstracts from Tempus have been accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium [1] - The symposium is scheduled to take place from January 8 to 10 in San Francisco, California [1] Group 2: Research Commitment - The research presented by Tempus at the ASCO GI symposium reflects the company's commitment to advancing progress in gastrointestinal cancers [1] - The presentations demonstrate the effectiveness of utilizing AI in cancer research [1]